HOME >> MEDICINE >> NEWS
ACP releases 5th Edition of its respected ethics manual

PHILADELPHIA -- (April 5, 2005) The American College of Physicians (ACP) has published the fifth edition of its Ethics Manual. The ACP Ethics Manual appears in the April 5, 2005, issue of Annals of Internal Medicine, published by ACP.

The new Ethics Manual revisits and expands on issues of earlier editions, such as patient privacy and confidentiality, complementary and alternative medicine, end-of-life care, physician-assisted suicide, decisions about reproduction, managed care ethics, and research ethics. Its new topics include sections on chaperones and privacy, gifts from patients, selling products out of the office, health and human rights, patient safety, strikes and joint actions, and consultation and shared care.

The ACP Ethics Manual is written primarily for doctors of internal medicine but has been widely used by other physicians and is often cited in medical and ethical literature. The first ACP Ethics Manual was published in 1984. This edition is an update of the 1998 fourth edition.

"ACP's Ethics Manual provides an ethical framework to help physicians make complex decisions related to clinical practice and medical research in a changing environment," said William E. Golden, MD, ACP Regent and chair of the ACP ethics and human rights committee that developed the new manual.

"Many aspects of medicine are fundamental and timeless, and those need to be regularly reaffirmed," says Lois Snyder, JD, director of the ACP's Center for Ethics and Professionalism and staff author of the manual. "Medical practice and the context in which care is delivered obviously don't stand still, though. The fifth edition of the Ethics Manual examines emerging issues in medical ethics faced by doctors and their patients and revisits older issues that are still pertinent."

The fifth revision of the Ethics Manual was developed by the ACP ethics and human rights committee over the course of two years. Sections were reviewed by more than 24 experts.
'"/>


8-Apr-2005


Page: 1 2

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. JRRD releases single-topic issue on pain and pain management
3. American College of Physicians releases new patient education resources
4. JRRD releases single-topic issue focused on vision rehabilitation
5. The AGA Institute releases report on the future of gastroenterology
6. Osteoarthritis initiative releases first data
7. ESC releases updated Guidelines for the Management of Stable Angina Pectoris
8. The ESC releases guidance document on Cardiac Rhythm Management product performance
9. Heart Rhythm Society releases draft recommendations on pacemakers, ICDs on April 26
10. ACP releases annual report on The State of the Nations Health Care
11. USP releases national report

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ACP releases Edition its respected ethics manual

(Date:5/21/2013)... Colo. (May 21, 2013) Research into genetic features ... University of Colorado School of Medicine may lead to ... a paper published online by JAMA . , ... predict survival in some cases of pulmonary fibrosis, a ... years. As a result of the study, researchers may ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 While ... is synonymous with comprehensive travel guides. Brunswick Plantation & ... golf packages that include access to 27 holes of ... golf courses in North Carolina, knowing the Top ... and Lodges takes away the overwhelming task of selecting ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
(Date:5/21/2013)... as 35 percent of Mexican young adults may have ... Illinois scientist who conducted a study at the Universidad ... inherited genetic risk factors from both parents were already ... waist than those who hadn,t. They also had slightly ... of I professor of food science and human nutrition. ...
Breaking Medicine News(10 mins):Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Genetic risk for obesity found in many Mexican young adults 2
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
Cached News: